$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

$eltp Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000114420413045859 Filed on August 14, 2013

Income Statement

Concept	2013 Q2	2012 Q2
Revenue	$722.0K	$578.6K
YoY Change	24.79%
Cost Of Revenue	$579.0K	$454.4K
YoY Change	27.43%
Gross Profit	$143.0K	$124.2K
YoY Change	15.14%
Gross Profit Margin	19.81%	21.47%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development		$196.9K
YoY Change
% of Gross Profit		158.53%
Depreciation & Amortization	$109.6K	$118.4K
YoY Change	-7.5%	-1.3%
% of Gross Profit	76.61%	95.37%
Operating Expenses	$1.118M	$610.0K
YoY Change	83.29%
Operating Profit	-$976.0K	-$485.8K
YoY Change	100.92%
Interest Expense	$74.78K	$58.54K
YoY Change	27.74%
% of Operating Profit
Other Income/Expense, Net	$2.095M
YoY Change
Pretax Income	$921.7K
YoY Change
Income Tax	$0.00
% Of Pretax Income	0.0%
Net Earnings	$922.0K	-$10.52M
YoY Change	-108.76%
Net Earnings / Revenue	127.7%	-1818.68%
Basic Earnings Per Share	$0.00	-$0.03
Diluted Earnings Per Share	$0.00	-$0.03
COMMON SHARES
Basic Shares Outstanding	388.0M shares
Diluted Shares Outstanding	580.4M shares

Balance Sheet

Concept	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$230.0K	$480.0K
YoY Change	-52.08%	-72.73%
Cash & Equivalents	$231.1K	$475.1K
Short-Term Investments
Other Short-Term Assets	$120.0K	$80.00K
YoY Change	50.0%	-11.11%
Inventory	$938.6K	$360.0K
Prepaid Expenses
Receivables	$499.1K	$500.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.785M	$1.420M
YoY Change	25.71%	-46.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.958M	$4.190M
YoY Change	-5.53%	-0.95%
Goodwill
YoY Change
Intangibles	$712.9K
YoY Change
Long-Term Investments	$3.340M	$3.340M
YoY Change	0.0%	-0.6%
Other Assets	$590.0K	$580.0K
YoY Change	1.72%	-6.45%
Total Long-Term Assets	$8.607M	$8.770M
YoY Change	-1.86%	-0.57%
TOTAL ASSETS
Total Short-Term Assets	$1.785M	$1.420M
Total Long-Term Assets	$8.607M	$8.770M
Total Assets	$10.39M	$10.19M
YoY Change	1.98%	-11.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.280M	$1.310M
YoY Change	-2.29%	22.43%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.990M	$3.400M
YoY Change	17.35%	0.0%
Total Short-Term Liabilities	$5.310M	$4.760M
YoY Change	11.56%	2.81%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$93.82K	$28.78M
YoY Change	-99.67%	-37.04%
Total Long-Term Liabilities	$11.48M	$28.78M
YoY Change	-60.1%	-37.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.310M	$4.760M
Total Long-Term Liabilities	$11.48M	$28.78M
Total Liabilities	$16.79M	$33.55M
YoY Change	-49.95%	-33.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$127.5M
YoY Change
Common Stock	$121.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$306.8K
YoY Change
Treasury Stock Shares	100.0K shares
Shareholders Equity	-$6.400M	-$23.36M
YoY Change
Total Liabilities & Shareholders Equity	$10.39M	$10.19M
YoY Change	1.98%	-11.31%

Cashflow Statement

Concept	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	$922.0K	-$10.52M
YoY Change	-108.76%
Depreciation, Depletion And Amortization	$109.6K	$118.4K
YoY Change	-7.5%	-1.3%
Cash From Operating Activities	-$355.0K	-$297.4K
YoY Change	19.39%	-223.91%
INVESTING ACTIVITIES
Capital Expenditures	-$50.00K	-$20.00K
YoY Change	150.0%	-50.0%
Acquisitions
YoY Change
Other Investing Activities	-$80.00K	-$50.00K
YoY Change	60.0%	-80.77%
Cash From Investing Activities	-$134.9K	-$71.94K
YoY Change	87.5%	-76.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$400.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$352.0K	$176.0K
YoY Change	100.04%
NET CHANGE
Cash From Operating Activities	-$355.0K	-$297.4K
Cash From Investing Activities	-$134.9K	-$71.94K
Cash From Financing Activities	$352.0K	$176.0K
Net Change In Cash	-$137.9K	-$193.4K
YoY Change	-28.67%	222.25%
FREE CASH FLOW
Cash From Operating Activities	-$355.0K	-$297.4K
Capital Expenditures	-$50.00K	-$20.00K
Free Cash Flow	-$305.0K	-$277.4K
YoY Change	9.97%	-199.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	231102	USD
CY2013Q2	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	543434	USD
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	690000000	shares
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	690000000	shares
CY2013Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2013Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2013Q2	eltp	Bond Issue Costs BondIssueCosts	354453	USD
CY2013Q2	eltp	Accumulated Amortization Of Bond AccumulatedAmortizationOfBond	-111064	USD
CY2013Q2	eltp	Unamortization Of Bond UnamortizationOfBond	243389	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	369023	USD
CY2013Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	499083	USD
CY2013Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	665154	USD
CY2013Q2	us-gaap	Inventory Net InventoryNet	938624	USD
CY2013Q1	us-gaap	Inventory Net InventoryNet	1358146	USD
CY2013Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	116218	USD
CY2013Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	151051	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	1785027	USD
CY2013Q1	us-gaap	Assets Current AssetsCurrent	2543374	USD
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3958495	USD
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4028943	USD
CY2013Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	712922	USD
CY2013Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	694426	USD
CY2013Q2	us-gaap	Cost Method Investments CostMethodInvestments	3329322	USD
CY2013Q1	us-gaap	Cost Method Investments CostMethodInvestments	3329322	USD
CY2013Q2	us-gaap	Security Deposit SecurityDeposit	14314	USD
CY2013Q1	us-gaap	Security Deposit SecurityDeposit	14314	USD
CY2013Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	348650	USD
CY2013Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	267820	USD
CY2013Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	243389	USD
CY2013Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	246934	USD
CY2013Q2	eltp	Assets Noncurrent Excluding Property Plant And Equipment And Intangible Assets AssetsNoncurrentExcludingPropertyPlantAndEquipmentAndIntangibleAssets	3935675	USD
CY2013Q1	eltp	Assets Noncurrent Excluding Property Plant And Equipment And Intangible Assets AssetsNoncurrentExcludingPropertyPlantAndEquipmentAndIntangibleAssets	3858390	USD
CY2013Q2	us-gaap	Assets Assets	10392119	USD
CY2013Q1	us-gaap	Assets Assets	11125133	USD
CY2013Q2	us-gaap	Secured Debt Current SecuredDebtCurrent	3385000	USD
CY2013Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	3385000	USD
CY2013Q2	eltp	Short Term Loans And Current Portion Of Long Term Debt ShortTermLoansAndCurrentPortionOfLongTermDebt	604621	USD
CY2013Q1	eltp	Short Term Loans And Current Portion Of Long Term Debt ShortTermLoansAndCurrentPortionOfLongTermDebt	606296	USD
CY2013Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1283739	USD
CY2013Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1325126	USD
CY2013Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13333	USD
CY2013Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13333	USD
CY2013Q2	eltp	Preferred Share Derivative Interest Payable PreferredShareDerivativeInterestPayable	23584	USD
CY2013Q1	eltp	Preferred Share Derivative Interest Payable PreferredShareDerivativeInterestPayable	27500	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5310277	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5357255	USD
CY2013Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	148890	USD
CY2013Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	152223	USD
CY2013Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	93822	USD
CY2013Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	91571	USD
CY2013Q2	eltp	Derivative Liability Preferred Shares DerivativeLiabilityPreferredShares	6273022	USD
CY2013Q1	eltp	Derivative Liability Preferred Shares DerivativeLiabilityPreferredShares	6334621	USD
CY2013Q2	eltp	Derivative Liability Warrants DerivativeLiabilityWarrants	4966391	USD
CY2013Q1	eltp	Derivative Liability Warrants DerivativeLiabilityWarrants	7862848	USD
CY2013Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	11482125	USD
CY2013Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	14441263	USD
CY2013Q2	us-gaap	Liabilities Liabilities	16792402	USD
CY2013Q1	us-gaap	Liabilities Liabilities	19798518	USD
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	395787	USD
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	374495	USD
CY2013Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	121020480	USD
CY2013Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	119690336	USD
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-127509709	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-128431375	USD
CY2013Q2	us-gaap	Treasury Stock Value TreasuryStockValue	306841	USD
CY2013Q2	eltp	Change In Fair Value Of Preferred Share Derivatives ChangeInFairValueOfPreferredShareDerivatives	-900838	USD
CY2012Q2	eltp	Change In Fair Value Of Preferred Share Derivatives ChangeInFairValueOfPreferredShareDerivatives	-4643484	USD
CY2013Q2	eltp	Interest Expense Preferred Share Derivatives InterestExpensePreferredShareDerivatives	23584	USD
CY2012Q2	eltp	Interest Expense Preferred Share Derivatives InterestExpensePreferredShareDerivatives	55077	USD
CY2012Q2	eltp	Discount In Series E Issuance Attributable To Beneficial Conversion Features DiscountInSeriesEIssuanceAttributableToBeneficialConversionFeatures	187500	USD
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1897258	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	921666	USD
CY2013Q2	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	0	USD
CY2012Q2	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	-3000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	921666	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-10522095	USD
CY2013Q1	us-gaap	Treasury Stock Value TreasuryStockValue	306841	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10392119	USD
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11125133	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	-6400283	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	-8673385	USD
CY2012Q2	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	379697	USD
CY2013Q2	us-gaap	Royalty Revenue RoyaltyRevenue	173255	USD
CY2012Q2	us-gaap	Royalty Revenue RoyaltyRevenue	128495	USD
CY2013Q2	us-gaap	Contracts Revenue ContractsRevenue	5000	USD
CY2012Q2	us-gaap	Contracts Revenue ContractsRevenue	70364	USD
CY2013Q2	us-gaap	Sales Revenue Net SalesRevenueNet	721689	USD
CY2012Q2	us-gaap	Sales Revenue Net SalesRevenueNet	578556	USD
CY2013Q2	us-gaap	Cost Of Revenue CostOfRevenue	579012	USD
CY2012Q2	us-gaap	Cost Of Revenue CostOfRevenue	454364	USD
CY2012Q2	us-gaap	Gross Profit GrossProfit	124192	USD
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	196882	USD
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	364961	USD
CY2013Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	9487	USD
CY2012Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	6113	USD
CY2012Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	41998	USD
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	609954	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-975592	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-485762	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	74778	USD
CY2012Q2	us-gaap	Interest Expense InterestExpense	58539	USD
CY2013Q2	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	2896457	USD
CY2012Q2	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	-5088733	USD
CY2012Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2012Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2013Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	387969981	shares
CY2013Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	580388867	shares
CY2013Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	27500	USD
CY2013Q2	eltp	Conversion Of Series B Series C And Series E Preferred Shares Into Common Shares Value ConversionOfSeriesBSeriesCAndSeriesEPreferredSharesIntoCommonSharesValue	962436	USD
CY2013Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9487	USD
CY2013Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	47987	USD
CY2013Q2	eltp	Stock Issued During Period Value Payment Of Directors Fees StockIssuedDuringPeriodValuePaymentOfDirectorsFees	0	USD
CY2013Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	400000	USD
CY2013Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	109553	USD
CY2013Q2	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	351	USD
CY2012Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	118442	USD
CY2013Q2	eltp	Discount In Series E Issuance Attributable To Beneficial Conversion Features DiscountInSeriesEIssuanceAttributableToBeneficialConversionFeatures	0	USD
CY2013Q2	us-gaap	Paid In Kind Interest PaidInKindInterest	27500	USD
CY2013Q2	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	1899	USD
CY2013Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-166071	USD
CY2013Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-419522	USD
CY2013Q2	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-34833	USD
CY2013Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-43061	USD
CY2013Q2	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	-3333	USD
CY2013Q2	eltp	Increase Decrease In Derivative Interest Payable Net IncreaseDecreaseInDerivativeInterestPayableNet	-3916	USD
CY2013Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-355047	USD
CY2012Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-297383	USD
CY2013Q2	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	35561	USD
CY2013Q2	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	0	USD
CY2012Q2	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	7206	USD
CY2012Q2	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	15947	USD
CY2012Q2	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	40718	USD
CY2013Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-134887	USD
CY2012Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-71939	USD
CY2013Q2	eltp	Proceeds From Issuance Of Series E Convertible Preferred Stock ProceedsFromIssuanceOfSeriesEConvertiblePreferredStock	0	USD
CY2012Q2	eltp	Proceeds From Issuance Of Series E Convertible Preferred Stock ProceedsFromIssuanceOfSeriesEConvertiblePreferredStock	187500	USD
CY2013Q2	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	400000	USD
CY2013Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	47987	USD
CY2012Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9856	USD
CY2013Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	352013	USD
CY2012Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	175970	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-137921	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-193352	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	668407	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	475055	USD
CY2012Q2	us-gaap	Interest Paid InterestPaid	1669	USD
CY2012Q2	us-gaap	Income Taxes Paid IncomeTaxesPaid	3000	USD
CY2013Q2	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2013Q2	eltp	Commitment Shares Issued CommitmentSharesIssued	219296	USD
CY2013Q2	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	962436	USD
CY2013Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	774758	USD
CY2013Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	676726	USD
CY2013Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0	USD
CY2013Q2	eltp	Finite Lived Intangible Assets Acquired During Period FiniteLivedIntangibleAssetsAcquiredDuringPeriod	18496	USD
CY2013Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2013Q1	us-gaap	Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral	6334621	USD
CY2013Q2	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	415500	USD
CY2013Q1	eltp	Bond Issue Costs BondIssueCosts	354453	USD
CY2013Q1	eltp	Accumulated Amortization Of Bond AccumulatedAmortizationOfBond	-107519	USD
CY2013Q1	eltp	Unamortization Of Bond UnamortizationOfBond	246934	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	89112	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	90894	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	85344	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	87363	USD
CY2013Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2909	shares
CY2013Q2	eltp	Preferred Stock Conversion Shares PreferredStockConversionShares	89614600	shares
CY2013Q2	eltp	Preferred Stock Closing Price PreferredStockClosingPrice	0.07
CY2013Q2	us-gaap	Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral	6273022	USD
CY2013Q2	eltp	Operating Lease Description OperatingLeaseDescription	initial term of 5 years and 6 months and the Company has the option to renew the lease for two additional terms, each of 5 years
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	83259	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	435972	USD
CY2013Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	22584	USD
CY2012Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	22584	USD
CY2013Q2	us-gaap	Deferred Rent Credit DeferredRentCredit	70160	USD
CY2013Q1	us-gaap	Deferred Rent Credit DeferredRentCredit	68260	USD
CY2013Q2	eltp	Payments Received In Advance PaymentsReceivedInAdvance	200000	USD
CY2013Q1	eltp	Recognized Deferred Revenue RecognizedDeferredRevenue	34444	USD
CY2013Q2	us-gaap	Deferred Revenue Revenue Recognized DeferredRevenueRevenueRecognized	3333	USD
CY2013Q2	us-gaap	Deferred Revenue DeferredRevenue	162223	USD
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2752332	shares
CY2013Q2	eltp	Share Based Compensation Arrangement By Share Based Payment Award Non Vested Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonVestedOptionsOutstandingNumber	1156668	shares
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	921666	USD
CY2012Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10522095	USD
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1223977	USD
CY2012Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	0	USD
CY2013Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	192418886	shares
CY2012Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2013Q2	us-gaap	Subsequent Events Date SubsequentEventsDate	2013-08-09

Files In Submission

Name	View Source	Status
0001144204-13-045859-index-headers.html	Edgar Link	pending
0001144204-13-045859-index.html	Edgar Link	pending
0001144204-13-045859.txt	Edgar Link	pending
0001144204-13-045859-xbrl.zip	Edgar Link	pending
eltp-20130630.xml	Edgar Link	completed
eltp-20130630.xsd	Edgar Link	pending
eltp-20130630_cal.xml	Edgar Link	unprocessable
eltp-20130630_def.xml	Edgar Link	unprocessable
eltp-20130630_lab.xml	Edgar Link	unprocessable
eltp-20130630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R35.xml	Edgar Link	unprocessable
R36.htm	Edgar Link	pending
R36.xml	Edgar Link	unprocessable
R37.htm	Edgar Link	pending
R37.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R38.xml	Edgar Link	unprocessable
R39.htm	Edgar Link	pending
R39.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R40.htm	Edgar Link	pending
R40.xml	Edgar Link	unprocessable
R41.htm	Edgar Link	pending
R41.xml	Edgar Link	unprocessable
R42.htm	Edgar Link	pending
R42.xml	Edgar Link	unprocessable
R43.htm	Edgar Link	pending
R43.xml	Edgar Link	unprocessable
R44.htm	Edgar Link	pending
R44.xml	Edgar Link	unprocessable
R45.htm	Edgar Link	pending
R45.xml	Edgar Link	unprocessable
R46.htm	Edgar Link	pending
R46.xml	Edgar Link	unprocessable
R47.htm	Edgar Link	pending
R47.xml	Edgar Link	unprocessable
R48.htm	Edgar Link	pending
R48.xml	Edgar Link	unprocessable
R49.htm	Edgar Link	pending
R49.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R50.htm	Edgar Link	pending
R50.xml	Edgar Link	unprocessable
R51.htm	Edgar Link	pending
R51.xml	Edgar Link	unprocessable
R52.htm	Edgar Link	pending
R52.xml	Edgar Link	unprocessable
R53.htm	Edgar Link	pending
R53.xml	Edgar Link	unprocessable
R54.htm	Edgar Link	pending
R54.xml	Edgar Link	unprocessable
R55.htm	Edgar Link	pending
R55.xml	Edgar Link	unprocessable
R56.htm	Edgar Link	pending
R56.xml	Edgar Link	unprocessable
R57.htm	Edgar Link	pending
R57.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v351168_10q.htm	Edgar Link	pending
v351168_ex10-12.htm	Edgar Link	pending
v351168_ex10-15.htm	Edgar Link	pending
v351168_ex31-1.htm	Edgar Link	pending
v351168_ex31-2.htm	Edgar Link	pending
v351168_ex32-1.htm	Edgar Link	pending
v351168_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2013 Q2 Form 10-Q Financial Statement

#000114420413045859 Filed on August 14, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2013 Q2 Form 10-Q Financial Statement

#000114420413045859 Filed on August 14, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp